Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 19 articles:
HTML format
Text format



Single Articles


    August 2017
  1. MAMOUNAS EP, Kuehn T, Rutgers EJT, von Minckwitz G, et al
    Current approach of the axilla in patients with early-stage breast cancer.
    Lancet. 2017 Aug 14. pii: S0140-6736(17)31451.
    PubMed     Text format     Abstract available


  2. COLES CE, Griffin CL, Kirby AM, Titley J, et al
    Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial.
    Lancet. 2017 Aug 2. pii: S0140-6736(17)31145.
    PubMed     Text format     Abstract available


  3. JAGSI R
    Early-stage breast cancer: falling risks and emerging options.
    Lancet. 2017 Aug 2. pii: S0140-6736(17)31599.
    PubMed     Text format    


    June 2017
  4. THE LANCET
    Breast cancer targeted therapy: successes and challenges.
    Lancet. 2017;389:2350.
    PubMed     Text format    


    February 2017
  5. CAMERON D, Piccart-Gebhart MJ, Gelber RD, Procter M, et al
    11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
    Lancet. 2017 Feb 16. pii: S0140-6736(16)32616.
    PubMed     Text format     Abstract available


  6. SPECHT JM, Davidson NE
    Optimal duration of trastuzumab for early HER2-positive breast cancer.
    Lancet. 2017 Feb 16. pii: S0140-6736(17)30322.
    PubMed     Text format    


    January 2017
  7. THE LANCET
    Trastuzumab emtansine and cost-based decision making.
    Lancet. 2017;389:2.
    PubMed     Text format    


    November 2016
  8. CRISTOFANILLI M
    Metastatic breast cancer: focus on endocrine sensitivity.
    Lancet. 2016 Nov 28. pii: S0140-6736(16)32418.
    PubMed     Text format    


  9. ROBERTSON JF, Bondarenko IM, Trishkina E, Dvorkin M, et al
    Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
    Lancet. 2016 Nov 28. pii: S0140-6736(16)32389.
    PubMed     Text format     Abstract available


  10. HARBECK N, Gnant M
    Breast cancer.
    Lancet. 2016 Nov 16. pii: S0140-6736(16)31891.
    PubMed     Text format     Abstract available


    September 2016
  11. THE LANCET
    Balancing the benefits and risks of choice.
    Lancet. 2016;388:1129.
    PubMed     Text format    


    June 2016
  12. OHUCHI N, Suzuki A, Yamamoto S, Kuriyama S, et al
    Adjunctive ultrasonography for breast cancer screening - Authors' reply.
    Lancet. 2016;387:2381-2.
    PubMed     Text format    


  13. AUTIER P, Boniol M
    Adjunctive ultrasonography for breast cancer screening.
    Lancet. 2016;387:2380.
    PubMed     Text format    


  14. FUJITA T
    Adjunctive ultrasonography for breast cancer screening.
    Lancet. 2016;387:2380-1.
    PubMed     Text format    


  15. DALE A, Slade E, Heneghan C
    Adjunctive ultrasonography for breast cancer screening.
    Lancet. 2016;387:2379-80.
    PubMed     Text format    


    May 2016
  16. BERNSTEIN M
    Intraoperative radiation therapy for breast cancer: a patient's view.
    Lancet. 2016;387:1904-5.
    PubMed     Text format    


    April 2016
  17. STRNAD V, Uter W, Polgar C
    Partial breast irradiation and the GEC-ESTRO trial - Authors' reply.
    Lancet. 2016;387:1718-9.
    PubMed     Text format    


  18. VICINI F, Shah C, Arthur D, Khan A, et al
    Partial breast irradiation and the GEC-ESTRO trial.
    Lancet. 2016;387:1717-8.
    PubMed     Text format    


  19. VAIDYA JS, Bulsara M, Wenz F, Tobias JS, et al
    Partial breast irradiation and the GEC-ESTRO trial.
    Lancet. 2016;387:1717.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: